| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. YL-109 repressed the sphere-forming ability and the expression of stem cell markers in MDA-MB-231 mammosphere cultures. YL-109 increased the expression of carboxyl terminus of Hsp70-interacting protein (CHIP), which suppresses tumorigenic and metastatic potential of breast cancer cells by inhibiting the oncogenic pathway. YL-109 induced CHIP transcription because of the recruitment of the aryl hydrocarbon receptor (AhR) to upstream of CHIP gene in MDA-MB-231 cells. Consistently, the antitumor effects of YL-109 were depressed by CHIP or AhRknockdown in MDA-MB-231 cells [1]. in vivo: Mice treated with vehicle showed significantly enlarged tumors, whereas mice treated with YL-109 showed attenuated tumor growth using MCF-7 cells. Interestingly, YL-109 also suppressed tumor growth in mice injected with MDA-MB-231 cells. Compared with the vehicle control, YL-109 significantly reduced lung metastasis
| ln Vitro |
In breast cancer cells, YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell motility, proliferation, and invasiveness[1]. In MDA-MB-231 cells, YL-109 (1 μM) raises CHIP mRNA and protein levels[1].
|
|---|---|
| ln Vivo |
In vivo, YL-109 (15 mg/kg; sc every 2 days) suppresses the growth of tumors as well as the metastasis of breast cancer cells[1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: MCF-7 and MDA-MB-231 cells Tested Concentrations: 0.001, 0.01, 0.1, 1, 10 μM Incubation Duration: 96 hrs (hours) Experimental Results: Strongly inhibited cell proliferation of MCF -7 and MDA-MB-231 cells in a dose-dependent manner (IC50=85.8 nM and 4.02 μM, respectively). |
| Animal Protocol |
Animal/Disease Models: BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells[1]
Doses: 15 mg/kg Route of Administration: Sc every 2 days for 63 days Experimental Results: Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells. |
| References |
| Molecular Formula |
C14H11NO2S
|
|
|---|---|---|
| Molecular Weight |
257.31
|
|
| Exact Mass |
257.051
|
|
| CAS # |
36341-25-0
|
|
| Related CAS # |
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.327g/cm3
|
|
| Boiling Point |
446.448ºC at 760 mmHg
|
|
| Flash Point |
223.804ºC
|
|
| Index of Refraction |
1.685
|
|
| LogP |
3.677
|
|
| InChi Key |
KRVBOHJNAFQFPW-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C14H11NO2S/c1-17-12-8-9(6-7-11(12)16)14-15-10-4-2-3-5-13(10)18-14/h2-8,16H,1H3
|
|
| Chemical Name |
4-(1,3-benzothiazol-2-yl)-2-methoxyphenol
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (11.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 3 mg/mL (11.66 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (11.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8864 mL | 19.4318 mL | 38.8636 mL | |
| 5 mM | 0.7773 mL | 3.8864 mL | 7.7727 mL | |
| 10 mM | 0.3886 mL | 1.9432 mL | 3.8864 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
